Cytochrome P450 Enzymes: |
---|
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 2.161E-14 | 4.705E-10 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 1.149E-09 | 5.396E-06 | AKR1B1, CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, HSD17B2, NPC1 |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.487E-09 | 5.396E-06 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 1.487E-09 | 5.396E-06 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 4.240E-09 | 1.319E-05 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 9.733E-09 | 2.355E-05 | CYP1A2, CYP2C9, CYP3A4 |
BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 1.990E-08 | 3.612E-05 | CA7, EGFR, HIF1A, MAPK1, NPC1, TNKS, TNKS2 |
MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 1.364E-07 | 1.856E-04 | CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 2.904E-07 | 3.011E-04 | CYP1A2, CYP2C19, CYP2C9 |
BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 4.771E-07 | 4.328E-04 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
MF | GO:0005488; binding | GO:0020037; heme binding | 8.484E-07 | 7.390E-04 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.096E-06 | 8.522E-04 | CA12, CA4, CA7 |
BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 1.635E-06 | 1.148E-03 | MAPK1, TNKS, TNKS2 |
CC | GO:0044464; cell part | GO:0032838; plasma membrane bounded cell projection cytoplasm | 2.185E-06 | 1.442E-03 | AKR1B1, HIF1A, MAPK1, MAPT |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.552E-06 | 1.588E-03 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
BP | Unclassified; | GO:0032844; regulation of homeostatic process | 3.016E-06 | 1.824E-03 | CA7, EGFR, HIF1A, MAPK1, NPC1, TNKS, TNKS2 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 3.185E-06 | 1.875E-03 | CYP1A2, CYP2C19, CYP2C9 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 4.234E-06 | 2.388E-03 | CYP1A2, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 5.640E-06 | 2.995E-03 | CYP2D6, CYP3A4 |
BP | GO:0007610; behavior | GO:0007610; behavior | 7.009E-06 | 3.469E-03 | EGFR, HIF1A, MAPK1, MAPT, NPC1, THRB, TP53 |
BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 1.067E-05 | 5.018E-03 | CYP1A2, EGFR, MAPK1 |
BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 1.127E-05 | 5.113E-03 | TNKS, TNKS2 |
BP | GO:0065007; biological regulation | GO:0032212; positive regulation of telomere maintenance via telomerase | 1.416E-05 | 6.035E-03 | MAPK1, TNKS, TNKS2 |
BP | GO:0008152; metabolic process | GO:0034754; cellular hormone metabolic process | 1.469E-05 | 6.035E-03 | AKR1B1, ALDH1A1, CYP3A4, HSD17B2 |
BP | GO:0050896; response to stimulus | GO:0034614; cellular response to reactive oxygen species | 1.469E-05 | 6.035E-03 | AKR1B1, EGFR, MAPK1, TP53 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.686E-05 | 6.557E-03 | CA12, CA4, CA7 |
CC | GO:0043226; organelle | GO:0043231; intracellular membrane-bounded organelle | 1.626E-05 | 6.556E-03 | AKR1B1, CA4, CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, EGFR, HIF1A, HSD17B10, KDM4E, LMNA, MAPK1, MAPT, NFKB1, NPC1, RAB9A, RECQL, THRB, TNKS, TNKS2, TP53 |
CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 2.558E-05 | 9.603E-03 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, EGFR, HSD17B2, RAB9A |
Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|
hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 3.210E-08 | 4.278E-06 | CYP2C9; CYP2D6; CYP1A2; CYP3A4; CYP2C19 |
hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 6.112E-08 | 4.278E-06 | CYP2C9; CYP1A2; CYP3A4; CYP2C19 |
hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 1.793E-06 | 4.444E-05 | MAPK1; TP53; EGFR; NFKB1 |
hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.685E-06 | 4.444E-05 | CYP2C9; CYP1A2; ALDH1A1; CYP3A4 |
hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 1.905E-06 | 4.444E-05 | MAPK1; TP53; HIF1A; EGFR |
hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 5.946E-06 | 9.249E-05 | MAPK1; TP53; EGFR; NFKB1 |
hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 2.690E-06 | 5.379E-05 | CYP2C9; CYP2D6; CYP1A2; CYP3A4 |
hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 1.063E-05 | 1.488E-04 | MAPK1; HIF1A; EGFR; NFKB1 |
hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 4.287E-06 | 7.502E-05 | CYP2C9; CYP1A2; CYP3A4; CYP2C19 |
hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 2.079E-05 | 2.239E-04 | MAPK1; MAPT; TP53; EGFR; NFKB1 |
hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.481E-05 | 1.885E-04 | CYP2C9; CYP2D6; MAPK1; CYP2C19 |
hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 1.473E-06 | 4.444E-05 | CA12; CA4; CA7 |
hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 1.819E-05 | 2.123E-04 | THRB; MAPK1; TP53; HIF1A |
hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 3.562E-05 | 3.116E-04 | LMNA; MAPK1; TP53; NFKB1 |
hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 2.913E-05 | 2.719E-04 | MAPK1; TP53; EGFR; NFKB1 |
hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 5.799E-05 | 4.510E-04 | MAPK1; TP53; EGFR |
hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 2.260E-05 | 2.260E-04 | MAPK1; TP53; EGFR |
hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 4.640E-05 | 3.821E-04 | MAPK1; TP53; EGFR |
hsa05214 | Glioma_Homo sapiens_hsa05214 | 9.064E-05 | 6.345E-04 | MAPK1; TP53; EGFR |
hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.692E-04 | 9.476E-04 | MAPK1; HIF1A; TP53; EGFR; NFKB1 |
hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 1.506E-04 | 9.166E-04 | MAPK1; TP53; HIF1A; EGFR |
hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 1.630E-04 | 9.476E-04 | CYP2C9; HSD17B2; CYP1A2; ALDH1A1; AKR1B1; CYP2C19; CYP3A4; HSD17B10 |
hsa05218 | Melanoma_Homo sapiens_hsa05218 | 1.180E-04 | 7.864E-04 | MAPK1; TP53; EGFR |
hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 1.281E-04 | 8.154E-04 | MAPK1; TP53; NFKB1 |
hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 6.443E-05 | 4.748E-04 | CYP1A2; HSD17B2; CYP3A4 |
hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 3.348E-04 | 1.803E-03 | MAPK1; HIF1A; EGFR |
hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 6.387E-04 | 2.981E-03 | MAPK1; TP53; EGFR; NFKB1 |
hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 5.546E-04 | 2.773E-03 | MAPK1; TP53; NFKB1 |
hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 5.546E-04 | 2.773E-03 | MAPK1; TP53; NFKB1 |
hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 1.069E-03 | 4.401E-03 | MAPK1; TP53; EGFR; NFKB1 |
hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 9.803E-04 | 4.159E-03 | MAPK1; TP53; NFKB1 |
hsa05162 | Measles_Homo sapiens_hsa05162 | 7.982E-04 | 3.492E-03 | RAB9A; TP53; NFKB1 |
hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 2.589E-03 | 9.858E-03 | MAPK1; TP53; NFKB1 |
hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 1.468E-03 | 5.873E-03 | MAPK1; MAPT; HSD17B10 |
hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 3.452E-03 | 1.128E-02 | MAPK1; EGFR; NFKB1 |
hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 2.960E-03 | 1.063E-02 | MAPK1; HIF1A |
hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 2.676E-03 | 9.858E-03 | MAPK1; NFKB1 |
hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 3.157E-03 | 1.078E-02 | MAPK1; TP53 |
hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 4.232E-03 | 1.268E-02 | MAPK1; NFKB1 |
hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 4.348E-03 | 1.268E-02 | MAPK1; NFKB1 |
hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 2.676E-03 | 9.858E-03 | MAPK1; NFKB1 |
hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 3.569E-03 | 1.136E-02 | MAPK1; HIF1A |
hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 8.163E-03 | 1.937E-02 | MAPK1; NFKB1 |
hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 4.348E-03 | 1.268E-02 | MAPK1; NFKB1 |
hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 3.157E-03 | 1.078E-02 | CYP2C9; CYP2C19 |
hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 3.784E-03 | 1.177E-02 | EGFR; NFKB1 |
hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 6.118E-03 | 1.616E-02 | MAPK1; EGFR |
hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 6.675E-03 | 1.683E-02 | MAPK1; EGFR |
hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 7.855E-03 | 1.896E-02 | MAPK1; EGFR |
hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 5.982E-03 | 1.611E-02 | TP53; NFKB1 |
hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 7.107E-03 | 1.746E-02 | TP53; NFKB1 |
hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 4.465E-03 | 1.276E-02 | MAPK1; EGFR |
hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 3.464E-03 | 1.128E-02 | MAPK1; NFKB1 |
hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 5.982E-03 | 1.611E-02 | MAPK1; NFKB1 |
hsa04540 | Gap junction_Homo sapiens_hsa04540 | 6.255E-03 | 1.622E-02 | MAPK1; EGFR |
hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 8.959E-03 | 2.023E-02 | MAPK1; NFKB1 |
hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 9.619E-03 | 2.138E-02 | MAPK1; NFKB1 |
hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 8.636E-03 | 1.982E-02 | MAPK1; NFKB1 |
hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 8.636E-03 | 1.982E-02 | MAPK1; NFKB1 |
hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 1.362E-02 | 2.931E-02 | MAPK1; NFKB1 |
hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 1.606E-02 | 3.356E-02 | MAPK1; EGFR |
hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 1.913E-02 | 3.938E-02 | MAPK1; EGFR |
hsa05133 | Pertussis_Homo sapiens_hsa05133 | 4.583E-03 | 1.283E-02 | MAPK1; NFKB1 |
hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 1.100E-02 | 2.407E-02 | MAPK1; NFKB1 |
hsa05164 | Influenza A_Homo sapiens_hsa05164 | 2.315E-02 | 4.697E-02 | MAPK1; NFKB1 |
hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 1.382E-02 | 2.931E-02 | MAPK1; EGFR |
hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 2.390E-02 | 4.779E-02 | MAPK1; NFKB1 |
hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 2.440E-02 | 4.811E-02 | TP53; NFKB1 |
hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 2.567E-02 | 4.991E-02 | TP53; NFKB1 |
hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 6.967E-04 | 3.146E-03 | MAPK1; TP53 |
hsa04320 | Dorso-ventral axis formation_Homo sapiens_hsa04320 | 6.033E-04 | 2.913E-03 | MAPK1; EGFR |
hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 6.732E-03 | 1.683E-02 | CYP1A2 |
ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
---|---|---|---|
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypothyroidism | E03 | THRB |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | THRB |
C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
C00-D49: Neoplasms | Brain cancer | C71, D33 | EGFR; EGFR |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; EGFR; EGFR |
C00-D49: Neoplasms | Colon cancer | C50 | EGFR |
K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR |
C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR |
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | EGFR |
A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Wound healing | T14.0-T14.1 | THRB |
G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | EGFR |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; EGFR; EGFR; EGFR; AKR1B1 |
C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
C00-D49: Neoplasms | Glioma | C71 | EGFR; EGFR |
C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; EGFR |
C00-D49: Neoplasms | Cancer | C00-C96 | HIF1A; TP53; MAPK1; NFKB1; EGFR |
L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4 |
C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; EGFR |
C00-D49: Neoplasms | Lung cancer | C33-C34 | EGFR |
C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperthyroidism | E05 | THRB |
C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | THRB |
C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
C00-D49: Neoplasms | Melanoma | C43 | EGFR |
C00-D49: Neoplasms | Ovarian cancer | C56 | EGFR; EGFR |
C00-D49: Neoplasms | Bladder cancer | C67 | EGFR |
E00-E89: Endocrine, nutritional and metabolic diseases | High cholesterol levels in blood | E78.0 | THRB |
C00-D49: Neoplasms | Pancreatic cancer | C25 | EGFR |
C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1 |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53 |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
C00-D49: Neoplasms | Prostate cancer | C61 | EGFR |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | EGFR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4 |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR |
C00-D49: Neoplasms | Gastric cancer | C16 | EGFR; EGFR |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
C00-D49: Neoplasms | Urethral cancer | NA | EGFR |
C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | EGFR; EGFR |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | EGFR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAPT |
C00-D49: Neoplasms | Breast cancer | C50 | EGFR; EGFR; EGFR |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1 |
A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A |
C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; TP53; MAPK1; EGFR |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR |
G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |